Figure 3.
PK profiles of FVIII:Ag in the presence or absence of recombinant VWF fragments in F8−/− mice. (A) Single-dose IV rhFVIII (200 IU/kg) alone or in combination with VWF-12 or VWF-13. (B) Single-dose subcutaneous (SC rhFVIII (1000 IU/kg) with or without VWF-12 or VWF-13. (C) Direct comparison of IV rhFVIII (200 IU/kg), subcutaneous rhFVIII (1000 IU/kg), with VWF-12 (1:3.1) and subcutaneous rhFVIII (1000 IU/kg) with VWF-13. Mean ± SD from 5 mice per group and time point.

PK profiles of FVIII:Ag in the presence or absence of recombinant VWF fragments in F8−/− mice. (A) Single-dose IV rhFVIII (200 IU/kg) alone or in combination with VWF-12 or VWF-13. (B) Single-dose subcutaneous (SC rhFVIII (1000 IU/kg) with or without VWF-12 or VWF-13. (C) Direct comparison of IV rhFVIII (200 IU/kg), subcutaneous rhFVIII (1000 IU/kg), with VWF-12 (1:3.1) and subcutaneous rhFVIII (1000 IU/kg) with VWF-13. Mean ± SD from 5 mice per group and time point.

Close Modal

or Create an Account

Close Modal
Close Modal